Compare Carlyle Group Inc (CG) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carlyle Group Inc vs Johnson & Johnson — how do they compare? Carlyle Group Inc trades at $48.11 (market cap $17.23B), while Johnson & Johnson trades at $260.57 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 36.3× Carlyle Group Inc's market cap, and Carlyle Group Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals.
| CG | JNJ | |
|---|---|---|
Market Cap | $17.23B | $626.09B |
Sector | Financials | Health |
52-Week High | $69.35 | $267.24 |
52-Week Low | $40.52 | $172.78 |
Dividend Yield | 2.9% | 2.06% |
Volume | — | 6,156,228 |
Enterprise Value | — | $654.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carlyle Group (CG) trades at $47.87, up 0.15% today, with a bullish technical signal and a consensus analyst price target of $59.14. Recent Q2 2026 earnings beat estimates, with EPS of $1.07 versus $0.91 expected, while revenue trends show volatility from $3.4B in 2024 to $3.2B in 2025. The stock is supported by strong institutional interest and dividend payments of $0.35 per share.
The outlook is positive with analyst buy ratings at 54%, but risks include declining net income margins and negative operating cash flows. Investment opportunity lies in valuation upside to the price target, though investors should monitor earnings consistency and macroeconomic impacts on asset management.
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
